Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Adjuvant Options Arrive for Melanoma

November 9th 2018

The treatment armamentarium for adjuvant melanoma has expanded rapidly, which has left the treatment challenge of selecting between immunotherapy and targeted therapy without any head-to-head comparative data.

Dr. Ascierto on Choosing Combinations in Treatment of Melanoma

October 24th 2018

Paolo A. Ascierto, MD, director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy at the National Tumor Institute Fondazione G. Pascale in Naples, discusses how to choose between combination therapies in the treatment of patients with melanoma.

Long-Term Data Sustain Dabrafenib/Trametinib RFS Benefit in BRAF+ Melanoma

October 22nd 2018

Long-term follow-up from the COMBI-AD trial continued to show a significant relapse-free survival advantage for patients with resected stage III BRAF-mutant melanoma treated with adjuvant dabrafenib plus trametinib.

Engineered Anti-MAGE-A T-Cells Show Early Promise

October 21st 2018

Genetically engineered T-cells targeting a common tumor antigen appeared safe and demonstrated some evidence of antitumor activity in a first-in-human clinical evaluation.

Dr. Flaherty Discusses BRAF Inhibitors in Melanoma

October 11th 2018

Keith T. Flaherty, MD, director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, professor of medicine, Harvard Medical School, discusses BRAF inhibitors for the treatment of patients with melanoma.

Dr. Zarour on Unmet Needs in Melanoma

October 10th 2018

Hassane M. Zarour, MD, professor of medicine, University of Pittsburgh, discusses unmet needs in melanoma.

Gene Signature Developed for High-Risk SCC

October 10th 2018

Gene expression-based biomarkers associated with disease recurrence in patients with cutaneous squamous cell carcinoma may help in identifying a population subset considered to have high-risk disease.

Dr. Postow on FDA Approval of Cemiplimab in Metastatic Cutaneous Squamous Cell Carcinoma

September 29th 2018

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of cemiplimab in patients with advanced or metastatic cutaneous squamous cell carcinoma.

Dr. Rischin on the FDA Approval of Cemiplimab for CSCC

September 29th 2018

Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, discusses the FDA approval of cemiplimab for the treatment of patients with cutaneous squamous cell carcinoma.

FDA Approves Cemiplimab for CSCC

September 29th 2018

The FDA has approved the PD-1 inhibitor cemiplimab (Libtayo) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC who are not candidates for curative surgery or curative radiation.

Adjuvant Therapy for Melanoma: Who, What, When?

September 28th 2018

More patients than ever before may now be good candidates for adjuvant therapy and derive long-term benefits from it, but new data and expanding treatment options have led to many new questions on how to optimize treatment for melanoma.

Weber Highlights Potency of Adjuvant Nivolumab in Melanoma

September 27th 2018

Jeffrey S. Weber, MD, PhD, discusses the promise of nivolumab in this setting and a general overview of the melanoma treatment landscape.

Dr. Eggermont Discusses Impact of Pembrolizumab in Melanoma

September 24th 2018

Alexander M. M. Eggermont, MD, PhD, director general of Gustave Roussy Cancer Campus Grand Paris in Villejuif, France, discusses the impact of pembrolizumab in melanoma.

Dr. Nghiem on Challenges With Immunotherapy in Merkel Cell Carcinoma

September 22nd 2018

Paul Nghiem, MD, PhD, Michael Piepkorn Endowed Chair in Dermatology Research, professor of Dermatology/Medicine at Fred Hutchinson Cancer Research Center, University of Washington Medicine, discusses challenges with immunotherapy in patients with Merkel cell carcinoma

Binimetinib/Encorafenib Combo Approved in Europe for BRAF+ Melanoma

September 21st 2018

The European Commission has approved the combination of encorafenib (Braftovi) and binimetinib (Mektovi) for the treatment of adult patients with BRAF V600–mutant unresectable or metastatic melanoma.

FDA Grants Pembrolizumab Priority Review for Merkel Cell Carcinoma

September 4th 2018

The FDA has granted a priority review to a supplemental biologics license application for pembrolizumab for the treatment of pediatric and adult patients with recurrent locally advanced or metastatic Merkel cell carcinoma.

Dr. Agarwala on Entinostat for Patients with Melanoma Who Progress on PD-1/PD-L1 Blockade

September 4th 2018

Sanjiv S. Agarwala, MD, chief of medical oncology and hematology, St. Luke’s Cancer Center, professor of medicine, Temple University School of Medicine, discusses the impact of entinostat for patients with melanoma who progress on a PD-1/PD-L1 blocking antibody.

Dr. Flaherty on the Tolerability of Encorafenib/Binimetinib in Melanoma

August 31st 2018

Keith T. Flaherty, MD, director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, professor of medicine, Harvard Medical School, discusses the tolerability of the combination of encorafenib (Braftovi) and binimetinib (Mektovi) in patients with melanoma.

Encorafenib/Binimetinib Combo Shows Best-In-Class Efficacy in Melanoma

August 31st 2018

Keith T. Flaherty, MD, discusses the clinical implications of the COLUMBUS trial of encorafenib plus binimetinib in patients with BRAF-mutated melanoma.

Cemiplimab Offers Hope in Metastatic CSCC

August 31st 2018

Danny Rischin, MD, MBBS, FRACP, discusses the potential for cemiplimab as a novel PD-1 inhibitor for patients with metastatic and locally advanced cutaneous squamous cell carcinoma.